Related Experiment Video

Updated: Nov 13, 2025

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

446

Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer

Xin Pan1, Tao Zhou, Yan-Hong Tai

  • 1State Key Laboratory of Proteomics, Institute of Basic Medical Sciences, China National Center of Biomedical Analysis, Beijing, China.

Nature Medicine
|May 17, 2011
PubMed

Insights

CUE domain-containing protein-2 (CUEDC2) drives endocrine resistance in breast cancer by reducing estrogen receptor-alpha (ER-α) stability. High CUEDC2 levels correlate with poor tamoxifen response and increased relapse risk.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Endocrine resistance is a significant challenge in breast cancer treatment.
  • Reduced estrogen receptor-alpha (ER-α) expression contributes to endocrine resistance, but the underlying mechanisms remain unclear.

Purpose of the Study:

  • To investigate the role of CUE domain-containing protein-2 (CUEDC2) in endocrine resistance in breast cancer.
  • To elucidate the mechanism by which CUEDC2 influences ER-α protein stability and tamoxifen responsiveness.

Main Methods:

  • Analysis of CUEDC2 and ER-α protein expression in breast cancer patient specimens.
  • Investigation of CUEDC2's effect on ER-α protein stability via the ubiquitin-proteasome pathway.
  • Assessment of tamoxifen responsiveness in breast cancer cells with varying CUEDC2 expression levels.

Main Results:

  • A significant inverse correlation was observed between CUEDC2 and ER-α protein expression in breast cancer tissues.
  • High CUEDC2 expression in tumors was associated with diminished tamoxifen treatment response and a greater likelihood of relapse.
  • Experimental overexpression of CUEDC2 in breast cancer cells reduced their sensitivity to tamoxifen.

Conclusions:

  • CUEDC2 plays a critical role in mediating endocrine resistance in breast cancer.
  • CUEDC2 modulates ER-α protein stability through the ubiquitin-proteasome pathway, impacting tamoxifen efficacy.
  • CUEDC2 represents a potential therapeutic target for overcoming endocrine resistance in breast cancer.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.9K
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

10.7K

Related Concept Videos

Cadherins in Tissue Organization01:19

Cadherins in Tissue Organization

The cadherins are a superfamily of cell adhesion molecules comprising over 180 variants, with specific tissues expressing a particular combination of cadherin types. Cadherins generally exhibit homophilic binding; i.e., cadherins on one cell bind to cadherins of the same or closely related type on another cell. Thus, cells of the same type have a specific affinity to bind to each other and sort themselves into clusters to form tissues.
Cell Sorting During Development
Cell sorting plays an...
3.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.5K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K